COVID Antivirals And Pandemic Preparedness Will Drive Compelling Long Term Opportunity

Catalysts

About Traws Pharma

Traws Pharma is a clinical stage biopharmaceutical company developing oral antivirals for COVID 19 and pandemic influenza, alongside partnering opportunities in oncology.

What are the underlying business or industry changes driving this perspective?

• Advancement of ratutrelvir into Phase II studies targeting both PAXLOVID eligible and ineligible COVID patients positions Traws to address a large, under served treatment population. This can drive meaningful future revenue growth if clinical data are positive and support premium pricing.
• Persistent, year round COVID circulation, declining vaccine effectiveness in preventing infection and rising concern over Long COVID increase demand for effective, convenient oral antivirals. This could translate into a durable revenue stream and improved earnings power as ratutrelvir matures.
• Ongoing engagement with BARDA and the FDA to position tivoxavir marboxil for inclusion in national pandemic stockpiling efforts offers the potential for sizeable, lumpy procurement contracts that could lift top line revenue and improve operating leverage.
• Tivoxavir marboxil is designed to target highly virulent bird flu strains and broadly conserved influenza mechanisms at a time of expanding animal outbreaks. This could support adoption for both treatment and prevention and enhance long term revenue visibility and gross margin profile.
• Refocusing R&D spend from legacy oncology programs toward high value virology assets, combined with lower personnel costs, has already reduced quarterly net loss and provides a leaner cost base that can expand net margins as antiviral revenues begin to scale.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Traws Pharma's revenue will remain fairly flat over the next 3 years.
• Analysts are not forecasting that Traws Pharma will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Traws Pharma's profit margin will increase from -509.0% to the average US Pharmaceuticals industry of 19.6% in 3 years.
• If Traws Pharma's profit margin were to converge on the industry average, you could expect earnings to reach $547.4 thousand (and earnings per share of $0.03) by about June 2029, up from -$13.9 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.7x on those 2029 earnings, up from -0.9x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 14.7x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The long-term commercial potential of ratutrelvir depends on successful Phase II and subsequent late-stage trials in a rapidly evolving COVID landscape. Any failure to show clear clinical or safety advantages over PAXLOVID could limit physician adoption and pricing power, constraining revenue growth and delaying a path to positive earnings.
• Tivoxavir marboxil is strategically positioned for pandemic preparedness. However, the current low perceived human health risk from H5N1 and the FDA preference for human clinical data rather than the Animal Rule may slow BARDA stockpiling decisions and procurement volumes, creating uncertainty around large, lumpy government contracts and limiting visibility on future revenue and operating leverage.
• Traws remains a small, loss-making clinical stage company with just $13.1 million in cash, cash equivalents and short-term investments as of June 30, 2025 and no recurring product revenue. Delays in clinical timelines, stockpiling decisions or partnering outcomes could force dilutive capital raises that pressure the share price and weigh on per share earnings.
• The broader secular trend toward improved vaccines, competing antivirals and evolving standards of care for both COVID and influenza may compress the size of the addressable market or intensify pricing and reimbursement pressure. This would limit the company’s ability to scale revenue and sustain attractive net margins even if its drugs are approved.
• Management intends to extract value from legacy oncology assets via partnerships after recognizing a one time revenue boost from a terminated license. Failure to secure new, economically meaningful deals in a cautious biotech funding and licensing environment could reduce non-dilutive funding sources and keep total revenue and cash flows below what is implied by a rising share price.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $1.0 for Traws Pharma based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.8 million, earnings will come to $547.4 thousand, and it would be trading on a PE ratio of 41.7x, assuming you use a discount rate of 7.1%.
• Given the current share price of $0.83, the analyst price target of $1.0 is 16.8% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.